Braster SA
WSE:BRA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Braster SA
Total Liabilities & Equity
Braster SA
Total Liabilities & Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
Braster SA
WSE:BRA
|
Total Liabilities & Equity
zł18.6m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
13%
|
|
|
S
|
Sds Optic SA
WSE:SDS
|
Total Liabilities & Equity
zł16.2m
|
CAGR 3-Years
27%
|
CAGR 5-Years
36%
|
CAGR 10-Years
N/A
|
|
|
S
|
Scope Fluidics SA
WSE:SCP
|
Total Liabilities & Equity
zł141.7m
|
CAGR 3-Years
-28%
|
CAGR 5-Years
46%
|
CAGR 10-Years
N/A
|
|
|
M
|
Medinice SA
WSE:ICE
|
Total Liabilities & Equity
zł82.5m
|
CAGR 3-Years
24%
|
CAGR 5-Years
53%
|
CAGR 10-Years
N/A
|
|
|
M
|
Medicalgorithmics SA
WSE:MDG
|
Total Liabilities & Equity
zł105.9m
|
CAGR 3-Years
44%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
0%
|
|
|
A
|
Airway Medix SA
WSE:AWM
|
Total Liabilities & Equity
zł12.1m
|
CAGR 3-Years
25%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
-6%
|
|
Braster SA
Glance View
Braster SA engages in the development and manufacturing of medical devices for self-examination. The firm provides research and development on breast cancer. The company applies liquid crystals and liquid crystal emulsion formula that is used to produce liquid crystal matrix based on LCD technology, continuous film CLCF (Continuous Liquid Crystal Film) in the diagnosis of breast cancer. Its main product is Braster Tester, which is a device that uses thermographic liquid crystal matrices for diagnosing breast cancer; the device is made up of three film matrices covered with a liquid crystal mixture that allows thermal imaging. The firm cooperates with the Jagiellonian University, with the participation of the clinical trial conducted by Thermacrac, among others.
See Also
What is Braster SA's Total Liabilities & Equity?
Total Liabilities & Equity
18.6m
PLN
Based on the financial report for Mar 31, 2024, Braster SA's Total Liabilities & Equity amounts to 18.6m PLN.
What is Braster SA's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 10Y
13%
Over the last year, the Total Liabilities & Equity growth was -23%. The average annual Total Liabilities & Equity growth rates for Braster SA have been -24% over the past three years , -18% over the past five years , and 13% over the past ten years .
